Navigating the Controversies and Complexities of Implementing Lecanemab in the Veterans Affairs Health System.
The article focuses on the evolving landscape of Alzheimer's disease (AD) diagnosis and treatment, particularly the implementation of anti-amyloid therapies like lecanemab within the Veterans Health Administration (VHA). It highlights the shift from clinical diagnosis to biomarker-based confirmation...
| Publicado en: | Journal of the American Geriatrics Society Vol. 73; no. 10; pp. 2983 - 2986 |
|---|---|
| Autores principales: | , |
| Formato: | Artículo |
| Publicado: |
Wiley-Blackwell
Oct2025
|
| Materias: | |
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ssf&AN=188899888&site=ehost-live header: @attributes: shortDbName: ssf uiTerm: 188899888 longDbName: Social Sciences Full Text (H.W. Wilson) uiTag: AN controlInfo: bkinfo: jinfo: jid: 00028614 20Q jtl: Journal of the American Geriatrics Society issn: 00028614 maglogo: Y pubinfo: dt: Oct2025 vid: 73 iid: 10 pid: 480 pub: Wiley-Blackwell artinfo: ui: 188899888 10.1111/jgs.70073 ppf: 2983 ppct: 3 formats: tig: atl: Navigating the Controversies and Complexities of Implementing Lecanemab in the Veterans Affairs Health System. aug: au: Yang, Mia Chodosh, Joshua affil: Wake Forest University School of Medicine, Atrium Health Neurosciences‐ Charlotte, Wake Forest Baptist Internal Medicine‐ Geriatrics, Advocate Health, Winston Salem, USA NYU Grossman School of Medicine, Department of Medicine, New York, USA VA New York Harbor Healthcare System, New York, USA su: United States. Dept. of Veterans Affairs Human services programs Conflict (Psychology) Cost benefit analysis Therapeutic use of monoclonal antibodies Alzheimer's disease Medical care of veterans Surveys Conceptual structures Amyloid beta-protein precursor Chemical inhibitors sug: subj: Human services programs Conflict (Psychology) Cost benefit analysis United States. Dept. of Veterans Affairs Administration of Veterans' Affairs Therapeutic use of monoclonal antibodies Alzheimer's disease Medical care of veterans Surveys Conceptual structures Amyloid beta-protein precursor Chemical inhibitors keyword: anti‐amyloid therapies implementation lecanemab anti‐amyloid therapies implementation lecanemab ab: The article focuses on the evolving landscape of Alzheimer's disease (AD) diagnosis and treatment, particularly the implementation of anti-amyloid therapies like lecanemab within the Veterans Health Administration (VHA). It highlights the shift from clinical diagnosis to biomarker-based confirmation, emphasizing the complexities of diagnosing AD/ADRD due to co-existing conditions. The survey conducted by O'Donnell et al. reveals both facilitators and barriers to implementing lecanemab, including the need for extensive infrastructure and interdisciplinary collaboration. The article underscores the importance of proactive engagement from geriatricians in ensuring safe and effective delivery of these therapies, while also acknowledging the challenges posed by the modest efficacy and safety concerns associated with lecanemab. pubtype: Academic Journal doctype: Article src: R language: English refInfo: copyright: @attributes: flag: N holdings: @attributes: islocal: N |
|---|